Truist analyst Andrew Jeffrey raised the firm’s price target on Wex to $215 from $190 and keeps a Hold rating on the shares after its Q4 earnings beat. Having questiond its "goodness of fit", the company is showing its ability to drive faster-than- expected organic revenue growth across segments, the analyst tells investors in a research note. The firm maintains a neutral stance however to reflect the stock’s recent multiple expansion and greater contribution from low-multiple Healthcare custodial revenue.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on WEX: